Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,011 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini A. Evens AM, et al. Among authors: gautam a. Haematologica. 2022 May 1;107(5):1086-1094. doi: 10.3324/haematol.2021.278438. Haematologica. 2022. PMID: 34162178 Free PMC article.
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.
Straus D, Collins G, Walewski J, Zinzani PL, Grigg A, Sureda A, Illes A, Kim TM, Alekseev S, Specht L, Buccheri V, Younes A, Connors J, Forero-Torres A, Fenton K, Gautam A, Purevjal I, Liu R, Gallamini A. Straus D, et al. Among authors: gautam a. Leuk Lymphoma. 2020 Dec;61(12):2931-2938. doi: 10.1080/10428194.2020.1791846. Epub 2020 Aug 25. Leuk Lymphoma. 2020. PMID: 32842815
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study.
Hutchings M, Radford J, Ansell SM, Illés Á, Sureda A, Connors JM, Sýkorová A, Shibayama H, Abramson JS, Chua NS, Friedberg JW, Kořen J, LaCasce AS, Molina L, Engley G, Fenton K, Jolin H, Liu R, Gautam A, Gallamini A. Hutchings M, et al. Among authors: gautam a. Hematol Oncol. 2021 Apr;39(2):185-195. doi: 10.1002/hon.2838. Epub 2021 Feb 16. Hematol Oncol. 2021. PMID: 33462822 Free PMC article.
Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.
Bröckelmann PJ, McMullen S, Wilson JB, Mueller K, Goring S, Stamatoullas A, Zagadailov E, Gautam A, Huebner D, Dalal M, Illidge T. Bröckelmann PJ, et al. Among authors: gautam a. Br J Haematol. 2019 Jan;184(2):202-214. doi: 10.1111/bjh.15566. Epub 2018 Sep 21. Br J Haematol. 2019. PMID: 30239982 Free PMC article. Clinical Trial.
Brentuximab vedotin: targeting CD30 as standard in CTCL.
Prince HM, Gautam A, Kim YH. Prince HM, et al. Among authors: gautam a. Oncotarget. 2018 Feb 10;9(15):11887-11888. doi: 10.18632/oncotarget.24472. eCollection 2018 Feb 23. Oncotarget. 2018. PMID: 29552279 Free PMC article. No abstract available.
1,011 results